ReviewReview of epidemiology and management of atrial fibrillation in developing countries
Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. There have been many studies in Western countries reporting the prevalence of AF. Approximately 2.3 million American people and six million Europeans are affected by AF [1], [2]. The prevalence of AF in the general population in some Western countries ranges from 0.5% to 2% [3], [4], [5]. According to the Framingham study, the incidence of AF increases significantly with age. The incidence doubles with each decade after the age of 50 and reaches around 10% at the age of 80 years [6]. According to the Cardiovascular Health study, the prevalence of AF in patients older than 65 years old is 6.2% in men and 4.8% in women [7]. People with AF have an increased risk of stroke [8].
Risk factors for AF include old age, male sex, hypertension, heart failure, ischemic heart disease, valvular heart diseases, diabetes, obesity, hyperthyroidism, alcohol abuse, smoking, and pulmonary disease. Mainstay therapy for AF includes assessment of thromboembolic risk and stroke prevention, applying appropriate rate-control or rhythm-control strategies, and management of associated diseases [8], [9].
In developing countries, AF is a growing public health problem in the context of the epidemiologic transition from communicable to non-communicable diseases [10], [11], [12], [13], [14]. The effect of AF on mortality and morbidity is likely to be substantial. In addition, AF puts a great burden on the socioeconomic system in these countries. The estimated annual costs of AF are high in these countries [15]. Anticoagulant use and monitoring are major challenges for health system in developing countries. Accessibility to the monitoring tests for anticoagulants, unreliability of test results, lack of compliance of patients, and interactions with diet and complementary medicines are all substantial issues in developing countries [16], [17], [18].
However, there have been few published studies about AF in developing world. Therefore, the aim of this review is to examine the prevalence of AF, the associated medical conditions, the impacts of AF on stroke rate and the management of AF (antithrombotic therapy and rate or rhythm control strategy) in developing countries.
Section snippets
Methods
A literature search was conducted via MEDLINE and EMBASE (from 1990 to May 2012). Keywords used for searching included “atrial fibrillation”, “epidemiology”, “prevalence”, “risk factors”, “associated medical conditions”, “associated diseases”, “stroke”, “antithrombotic”, “anticoagulant”, “INR”, “rate control”, “rhythm control”, “developing country”, “developing world”, and the names of developing countries according to the classification of the World Bank [19]. The articles attained by this
Results
A total of 70 articles were included in the review. There were 16 articles from East Asia and the Pacific, 17 from Europe and Central Asia, 12 from Latin America and the Caribbean, 3 from the Middle East and North Africa, 9 from South Asia and 11 from sub-Saharan Africa. China had the leading number of articles (13 articles), followed by Brazil (7 articles), Pakistan (6 articles), Turkey (4 articles), and Bosnia and Herzegovina (3 articles). Russia Federation, Thailand, Romania, Serbia,
Discussion
The prevalence of AF in the general population in community based studies in this review ranged from 0.03% to 1.25%, which is similar to that reported in some developed countries such as North America, the United Kingdom and Iceland (from 0.5% to 1%) [3], [4], [90] but lower than the prevalence reported in Australia (4%) [91]. The low prevalence of AF in both studies in India (0.03% and 0.1%) may be related to the populations studied: one study was in people living high altitude in a tribal
Conclusion
The limited studies available suggest that in the developing world there is a significant prevalence of AF, which is predominantly associated with hypertension and rheumatic heart disease, and carries a high risk of stroke. Highly variable use of anticoagulants may be related to different health care and socioeconomic settings. Large studies of representative populations are needed to improve understanding of the epidemiology and management of AF in developing countries.
References (133)
- et al.
Epidemiology and natural history of atrial fibrillation: clinical implications
J Am Coll Cardiol
(2001) - et al.
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health study)
Am J Cardiol
(1994) - et al.
Atrial fibrillation
Lancet
(2012) - et al.
A global view on the development of non communicable diseases
Prev Med
(2012) - et al.
Growing epidemic of coronary heart disease in low- and middle-income countries
Curr Probl Cardiol
(2010) - et al.
Estimating the economic burden of atrial fibrillation in selected developing countries
Value Health
(2012) - et al.
Winning the war, far, in developing countries. Novel anticoagulants as a new weapon against stroke
Int J Cardiol
(2012) - et al.
Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort study
Int J Cardiol
(2011) - et al.
Ischemic stroke in Jordan 2000 to 2002: a two-year, hospital-based study
J Stroke Cerebrovasc Dis
(2004) Retrospective investigation of hospitalised patients with atrial fibrillation in mainland China
Int J Cardiol
(2005)